Neeraj Sood is a member of the National Academies committee on “A National Strategy for the Elimination of Hepatitis B and C”. He is professor and vice dean for research at the University of Southern California Sol Price School of Public Policy, and director of research at the Leonard D. Schaeffer Center for Health Policy & Economics.
Recent Posts by Neeraj Sood
Publicly traded companies in the pharmaceutical distribution system must disclose annual financial information to the SEC. Those reports provide some of the most reliable public information about how funds flow through the distribution system.
While the development of new antimicrobials to combat antimicrobial resistance would seem to offer high value, our current system offers insufficient incentives to invest in them. Policy interventions that dampen the tie between manufacturer profits and the volume of antimicrobial use are needed.
A novel strategy to improve access to hepatitis C medicines recommends that the firms producing hepatitis C treatments compete to license their patent to the federal government for use in neglected patients.
Editor’s Note: Anthem Blue Cross of California, the largest health insurance company in California, recently announced plans to increase insurance premiums by as much as 39 percent for people insured in their non-group health insurance plans. There are two competing narratives about...
March 17, 2010 | Insurance and Coverage
Editor’s Note: The post below by Jonathan Kolstad and Neeraj Sood prompted a comment from Jeff Lemieux, who directs the Policy and Research Center at America’s Health Insurance Plans, a health insurance industry group. See “Individual Market Premium Increases: The Debate...
March 12, 2010 | Insurance and Coverage